DRD1 and kidney cancer: The discussed tridirectional activity of the D1R agonist (tumor-suppressive, bone anti-resorbing, and bone pro-forming) presents dopamine D1 receptor as a possible therapeutic target for preventing metastatic bone loss in breast cancer and preferably other tumors associated with bone metastases, such as prostate or kidney cancer.